Abbott spin-out to initiate new study with Danish drug
A candidate drug from the Danish company Action Pharma, which was bought by Abbott for more than 100 million US dollars, will now continue in clinical trials through a spin-out company.
by Leonora Beck
Action Pharma’s sale of a promising candidate drug to Abbott is on the list of the ten biggest biotech deals in Denmark within the last 5 years, and now the US pharmaceutical group’s million-dollar purchased will continue in clinical phases in the hope that the candidate, AP214, will eventually go all the way to approval.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
